Connect with us

World News

EU Lists Rare Nerve Disorder as Side-Effect of J&J COVID-19 Vaccine

Brittany Jordan

Published

on


Vials labelled “COVID-19 Coronavirus Vaccine” and sryinge are seen in front of displayed Johnson & Johnson logo in this illustration taken, Feb. 9, 2021. (Dado Ruvic/Illustration/Reuters)

Europe’s medicines regulator said on Thursday it had added a rare nerve-degenerating disorder, Guillain-Barré syndrome, as a possible rare side effect from Johnson & Johnson’s COVID-19 vaccine after it reviewed 108 cases reported worldwide.

“After assessing the available data, PRAC considered that a causal relationship between COVID-19 vaccine Janssen and GBS is possible,” the European Medicines Agency said, referring to its safety committee, PRAC.

By Pushkala Aripaka

Brittany Jordan is an award-winning journalist who reports on breaking news in the U.S. and globally for the Federal Inquirer. Prior to her position at the Federal Inquirer, she was a general assignment features reporter for Newsweek, where she wrote about technology, politics, government news and important global events around the world. Her work has also appeared in the Washington Post, the South Florida Sun-Sentinel, Toronto Star, Frederick News-Post, West Hawaii Today, the Miami Herald, and more. Brittany enjoys food, travel, photography, and hoarding notebooks and journals. Her goal is to do more longform features journalism, narrative writing and documentary work, and to one day write a successful novel and screenplay.

Copyright © 2021 Federal Inquirer. All rights reserved.